Biotech/Merck’s sacituzumab tirumotecan is set to supersede chemotherapy in combination with Keytruda in first-line, ...
Australia’s regulator weighs in on debate about whether intention or function should decide regulatory status for AI products ...
Another positive study for AstraZeneca’s PD-L1 blocker Imfinzi could send it into a third bladder cancer population, while ...
The Swiss company's candidate has comfortably surpassed Lumakras and Krazati; significant survival data and an impressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results